Ionis – positive phase 3 study Olezarsen

Aescap portfolio company Ionis announced today that its medicine candidate Olezarsen has shown a statistically significant reduction in triglyceride levels in a phase 3 clinical study.

Ionis – positive phase 3 study Olezarsen
Lees verder

Rocket Pharmaceuticals up 39% on good news for Danon patients

Aescap portfolio company Rocket Pharmaceuticals yesterday went up 39% after it came to an agreement with the FDA that it only needs to enroll 12 patients in a pivotal clinical trial with their gene therapy for a fatal heart disease.

Rocket Pharmaceuticals up 39% on good news for Danon patients
Lees verder

Biotech, to time with a good feeling

Promising undervalued biotech companies offer an excellent opportunity for significant future returns. Waiting until the sector is back in the spotlight often results in a missed opportunity. As share prices will have risen by then.

Biotech, to time with a good feeling
Lees verder

UCB: An interesting biopharmaceutical growth story

UCB is a biopharma company with over 8 600 employees, headquartered in Brussels, Belgium The company develops and manufactures multiple medicines, sold in 40 countries. In this company showcase we describe why we think UCB is an interesting biopharmaceutical growth story, even after 95 years of existence.

UCB: An interesting biopharmaceutical growth story
Lees verder

Aescap Genetics Newsletter Q3 2022

From treatment of symptoms to cure. The number of genetic medicines that are so advanced in R&D that they are tested on humans has been increasing by an average of 27% per year since 2016.

Aescap Genetics Newsletter Q3 2022
Lees verder